TLIS (Talis Biomedical) LT-Debt-to-Total-Asset : 0.22 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Talis Biomedical's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.22.

Talis Biomedical's long-term debt to total assets ratio increased from Jun. 2023 (0.14) to Jun. 2024 (0.22). It may suggest that Talis Biomedical is progressively becoming more dependent on debt to grow their business.

Talis Biomedical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Talis Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical LT-Debt-to-Total-Asset Chart

Talis Biomedical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.18

Talis Biomedical Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.14	0.16	0.18	0.20	0.22

Talis Biomedical LT-Debt-to-Total-Asset Calculation

Talis Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	16.786	/	94.674
	=	0.18

Talis Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	15.877	/	72.699
	=

Talis Biomedical (OTCPK:TLIS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Talis Biomedical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Talis Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (OTCPK:TLIS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607

Website

https://talisbio.com

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

Executives

Andrew A Lukowiak	officer: President, other: Chief Scientific Officer	1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich	officer: Interim CFO	CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser	director, officer: President and CEO	561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan	officer: Sr. Vice President, R&D	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Moody John Roger Jr	officer: Chief Financial Officer	4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062